Scarica l'app Stockscreener
139.94
1.19%
-1.68
Dopo l'orario di chiusura:
140.01
0.07
+0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$141.62
Aprire:
$141.78
Volume 24 ore:
1.53M
Relative Volume:
1.07
Capitalizzazione di mercato:
$20.52B
Reddito:
$9.61B
Utile/perdita netta:
$1.53B
Rapporto P/E:
13.38
EPS:
10.46
Flusso di cassa netto:
$1.85B
1 W Prestazione:
+5.50%
1M Prestazione:
+5.85%
6M Prestazione:
-1.90%
1 anno Prestazione:
-31.72%
Intervallo 1D:
$137.14
$142.28
Intervallo di 1 settimana:
$131.52
$145.27
Portata 52W:
$110.03
$205.19
Biogen Inc Stock (BIIB) Company Profile
Nome
Biogen Inc
Settore
Industria
Telefono
(781) 464-2000
Indirizzo
225 BINNEY STREET, CAMBRIDGE, MA
Confronta BIIB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
139.94 | 20.47B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
742.91 | 659.07B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.76 | 428.83B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
213.00 | 374.37B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.42 | 245.16B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.05 | 213.51B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-21 | Ripresa | Truist | Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-04-04 | Downgrade | Argus | Buy → Hold |
| 2025-02-11 | Iniziato | Bernstein | Mkt Perform |
| 2025-01-02 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Downgrade | Stifel | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-12-09 | Downgrade | Jefferies | Buy → Hold |
| 2024-11-18 | Downgrade | Needham | Buy → Hold |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-31 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-14 | Reiterato | Needham | Buy |
| 2024-02-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2023-12-20 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-07-24 | Reiterato | UBS | Buy |
| 2023-05-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-04-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-10-13 | Aggiornamento | Stifel | Hold → Buy |
| 2022-10-07 | Aggiornamento | Argus | Hold → Buy |
| 2022-09-28 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-28 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Downgrade | Stifel | Buy → Hold |
| 2022-03-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Reiterato | Barclays | Equal Weight |
| 2022-02-04 | Reiterato | BofA Securities | Neutral |
| 2022-02-04 | Reiterato | Cowen | Outperform |
| 2022-02-04 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-04 | Reiterato | Needham | Buy |
| 2022-02-04 | Reiterato | Oppenheimer | Outperform |
| 2022-02-04 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Reiterato | Robert W. Baird | Neutral |
| 2022-02-04 | Reiterato | Wedbush | Neutral |
| 2022-02-04 | Reiterato | Wells Fargo | Equal Weight |
| 2022-02-04 | Reiterato | Wolfe Research | Peer Perform |
| 2022-01-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-01-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-06-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Reiterato | Truist | Buy |
| 2021-06-11 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-08 | Aggiornamento | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Reiterato | Barclays | Equal Weight |
| 2021-06-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-08 | Reiterato | Jefferies | Buy |
| 2021-06-08 | Reiterato | Morgan Stanley | Overweight |
| 2021-06-08 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Reiterato | Stifel | Buy |
| 2021-06-08 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-06-07 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Downgrade | DZ Bank | Buy → Hold |
| 2021-01-29 | Aggiornamento | Stifel | Hold → Buy |
| 2020-11-10 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-11-09 | Downgrade | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-11-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-04 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-11-04 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-07-27 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Downgrade | Citigroup | Neutral → Sell |
| 2020-04-23 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-01-27 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Downgrade | Robert W. Baird | Neutral → Underperform |
Mostra tutto
Biogen Inc Borsa (BIIB) Ultime notizie
Biogen Inc. $BIIB Stake Raised by B. Metzler seel. Sohn & Co. AG - MarketBeat
Biogen Shares Rally 1.43% on Key Therapeutic Advances and Strategic Expansion as $320M Volume Ranks 320th - AInvest
Biogen Showcases Lupus Pipeline But Investors Will Have To Wait For Data - insights.citeline.com
Western Digital, Adobe, Biogen See High Option Trading Volume - AInvest
Risk vs reward if holding onto Biogen Inc.2025 Analyst Calls & Reliable Trade Execution Plans - Newser
Stock Analysis | Biogen OutlookWeak Technicals Cloud Optimistic Fundamentals - AInvest
Investors Holding Back On Biogen Inc. (NASDAQ:BIIB) - 富途牛牛
Is it too late to sell Biogen Inc.Portfolio Gains Report & Daily Technical Forecast Reports - Newser
Biogen Thematic Pipeline Seminar: Lupus - MarketScreener
Should New Zorevunersen and LEQEMBI Launches Influence Biogen's (BIIB) Rare Disease Growth Strategy? - simplywall.st
Biogen Highlights Multiple Assets and Indications in Lupus - Biogen
Eisai and Biogen to launch new Alzheimer's treatment in the US - medwatch.com
Biogen, Eisai begin rolling FDA submissions for Leqembi injectable for starting dose - Seeking Alpha
These Stocks Are Moving the Most Today: Nvidia, Biogen, NIO, Spirit Aviation, and More - MSN
CW Advisors LLC Buys New Holdings in Biogen Inc. $BIIB - MarketBeat
Caisse DE Depot ET Placement DU Quebec Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Ieq Capital LLC Grows Stock Position in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. showing insider buying2025 Key Lessons & Smart Money Movement Alerts - khodrobank.com
Biogen Inc. $BIIB Stock Position Decreased by Canada Pension Plan Investment Board - MarketBeat
Can Biogen Inc. reach all time highs this year2025 Support & Resistance & Consistent Profit Trading Strategies - khodrobank.com
Will Biogen Inc. see short term momentumWeekly Volume Report & Free Reliable Trade Execution Plans - Newser
Biogen Inc. $BIIB Holdings Raised by Trexquant Investment LP - MarketBeat
Landscape Capital Management L.L.C. Takes $329,000 Position in Biogen Inc. $BIIB - MarketBeat
American Century Companies Inc. Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat
BNP Paribas Financial Markets Has $50.11 Million Stock Holdings in Biogen Inc. $BIIB - MarketBeat
The Game-Changing Potential of LEQEMBI® IQLIK™ in Early Alzheimer's Disease Treatment and Its Impact on Biogen and Eisai’s Market Position - AInvest
Visual analytics tools that track Biogen Inc. performanceJuly 2025 Final Week & Verified Technical Signals - Newser
Biogen Participating in the Cantor Global Healthcare Conference - Biogen
Real time breakdown of Biogen Inc. stock performance2025 Big Picture & Technical Buy Zone Confirmation - Newser
Evaluating Biogen Inc. with trendline analysisPrice Action & Reliable Volume Spike Trade Alerts - Newser
How institutional ownership impacts Biogen Inc. stockWeekly Earnings Recap & Low Risk High Win Rate Stock Picks - Newser
Biogen to Participate in Upcoming Healthcare Conferences - Biogen
Biogen Executive Makes a Significant Stock Sale - TipRanks
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Quantisnow
Biogen's Stock Surges 5.60% on Bullish Candlestick Pattern and Elevated Volume Amid Overbought Technical Indicators - AInvest
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status - Placera.se
Eisai, Biogen begin FDA submission for Alzheimer’s autoinjector - Investing.com
First At-Home Injection Option for Alzheimer's: Eisai's LEQEMBI IQLIK Could Transform Treatment Access - Stock Titan
Biogen Jumps 5.6% on Heavy Volume as Technicals Signal Bullish Reversal - AInvest
Can Biogen Inc. sustain its profitabilityWeekly Stock Recap & Growth Oriented Trade Recommendations - خودرو بانک
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen’s Surging Stock: Is a Breakthrough Imminent? - StocksToTrade
Is Biogen Inc. stock undervalued right nowAnalyst Downgrade & Weekly Market Pulse Alerts - خودرو بانک
Biogen (BIIB) Stock Is Up, What You Need To Know - Yahoo Finance
Biogen’s Sudden Surge: A Strategic Insight? - timothysykes.com
Biogen’s Strategic Moves: New Horizons or Risk? - StocksToTrade
Biogen Inc. (BIIB)’s Alzheimer’s Drug Leqembi Wins EU Nod, Now Approved in 48 Countries - MSN
Sector Update: Health Care Stocks Retreat Tuesday Afternoon - MarketScreener
Biogen Inc Azioni (BIIB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biogen Inc Azioni (BIIB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
9.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):